A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function

Overview of attention for article published in Journal for Immunotherapy of Cancer, September 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

twitter: 10 X users

patent: 2 patents

Citations

dimensions_citation: 57 Dimensions

Readers on

mendeley: 94 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 2 patents that reference this research output.

COMPOSITIONS AND METHODS FOR CELLULAR IMMUNOTHERAPY

Application WO-2023215725-A1

World Intellectual Property Organisation (WIPO)

FUSION PROTEIN OF ANTI-TIGIT ANTIBODY AND IL2 OR VARIANT THEREOF AND APPLICATION THEREOF

Application WO-2023045361-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.